Analysis of chemoradiotherapy for lung cancer using liquid biopsy

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K17174
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Sapporo Medical University
• Principal Investigator: Kitagawa Mio 札幌医科大学, 医学部, 助教 (30608922)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 肺癌 / 放射線治療 / リキッドバイオプシー

Outline of Final Research Achievements

The aim of this study was to predict individualized radiotherapy response and radiation lung injury in patients with stage III unresectable non-small cell lung cancer treated with chemoradiotherapy and immunotherapy. 10 ml of peripheral blood was drawn in 10 patients before the start of treatment, at the end of chemoradiotherapy and 2 weeks after the first immunotherapy administration. PBMC fractions were isolated and RNA TCR sequences were analyzed to confirm changes over time.
The results showed that the mean observation period from the start of treatment exceeded 15 months, with 6 cases of CR and 4 cases of PD in the chemoradiotherapy plus immunotherapy group, and that the change in TCR lepatore over time tended to be greater in the CR cases than in the PD cases.

Free Research Field

放射線腫瘍学

Academic Significance and Societal Importance of the Research Achievements

切除不能Ⅲ期肺癌の化学放射線療法および免疫療法を行った症例において、化学放射線療法前後および免疫療法前後でのTCRレパトアを調べることで、放射線治療の効果予測に利用できる可能性を示した。今後症例数を増やして、より高い精度での治療効果を予測する方法の確立を目指す。